Clinical DataUpdated analyses from the Phase 2 AURORA trial showed that treatment with bitopertin in erythropoietic protoporphyria patients elicited a meaningful impact on key aspects of EPP, providing more insights into the drug’s disease modifying effect.
Financial PositionThe company’s current cash position of $500.9M is expected to fund its planned operational plans into 2027.
Market OpportunityThe commercial opportunity of MF CKD associated anemia is huge, and there is no effective treatment to-date.